Characteristics and impact factors of SARS-CoV-2 infection in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma receiving chimeric antigen receptor T-cell therapy

• Published in: Zhōnghuá xuèyèxué zázhì 2023-10, Vol.44 (10), p.825-831
• Main Authors: Ge, T, Liu, H, Wang, Z H, Cao, Y, Zhang, Y C, Huang, L, Qian, W B, Zhou, X X
• Format: Article
• Language: Chinese
• Subjects: Adult; Cell- and Tissue-Based Therapy; COVID-19 - therapy; Humans; Lymphoma, B-Cell - therapy; Middle Aged; Receptors, Chimeric Antigen; Retrospective Studies; SARS-CoV-2
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2023.10.006

To explore the clinical characteristics and treatment of COVID-19 infection in patients with relapsed/refractory B-cell non-Hodgkin lymphoma before and after receiving chimeric antigen receptor T-cell therapy, and study the influencing factors of severe COVID-19 infection in these patients. The data of 59 patients with relapsed/refractory B-cell non-Hodgkin lymphoma who received chimeric antigen receptor T-cell therapy at the Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology and Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University between December 2017 and February 2023, and who were infected with novel coronavirus between December 2022 and February 2023 were retrospectively studied. Patients were divided into light, medium, severe, and critical groups, and the differences between the groups were analyzed using the chi-square test. A univariate logistic regression model was used to evaluate the contrib